ABSTRACT
Background: Breast cancer is now the most common malignant tumor in women. Pathway specific therapy is the future of cancer management. Stathmin, a microtubule destabilizing cytosolic phosphoprotein which has profound influence on cell proliferation, differentiation and cellular motility is an accurate signature IHC marker of PI3K pathway. From overexpression of Stathmin in breast carcinoma one get information about disease progression, prognosis, drug resistance and change in treatment modality. Objective:1. To study and compare the result of Stathmin with level of Estrogen Receptor, Progesterone Receptor and Her-2-neu expression in breast carcinoma. 2. To study Stathmin expression in relation to staging, grading and type of breast cancer. 3. To study the possibility of role of Stathmin as a therapeutic target in breast carcinoma. Methods: A cross- sectional study was done. All cases were grossly and microscopically examined and were subjected to immunohistochemical stains of Estrogen, Progesterone, Her-2-neu, Stathmin and were correlated to staging and grading. Statistical Analysis: There were altogether 41 cases. In primary breast carcinoma specimens the Stathmin levels were measured by immunohistochemistry and graded from 0 – 3. Scores more than 3 were high expressors with more than 50% tumor cells showing positivity. Conclusion: Stathmin over expression in breast carcinoma seems to co relate with loss of Estrogen receptors and Progesterone receptors